China-based EpimAb Biotherapeutics has successfully progressed its lead cancer asset - a bispecific antibody that simultaneously targets EGFR and cMET - into Phase I/II trials. The start-up is on track with its plan to build a proprietary pipeline organically, using its FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform, its chief operating and chief business officer told Scrip.
EMB01 is a bispecific antibody that simultaneously targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), two validated...








